BLASINGLE-USEVIALPriority Review
Approved
Nov 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 39m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTIVASE (alteplase) is a tissue plasminogen activator (tPA) indicated for thrombolytic therapy in acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. It works by converting plasminogen to plasmin, directly dissolving fibrin clots. This recombinant protein was the first genetically engineered thrombolytic agent approved by the FDA.
LOE Approaching
As LOE approaches, brand teams are likely consolidating and transitioning focus to lifecycle extension strategies, retention, and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Started Nov 2022
113,035 enrolled
Stroke
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Started Jul 2022
3,058 enrolled
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
Started Jun 2021
1,489 enrolled
Stroke
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
Started Dec 2020
104 enrolled
Acute Respiratory Distress Syndrome
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
Started Jun 2020
30 enrolled
Healthy
Worked on ACTIVASE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.